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After accounting for age, gender, risk factors, medications, coronary history, exercise 
capacity, chronotropic response, and heart rate recovery, VEA during recovery remained 
predictive of death (adjusted HR 1.5, 95% CI 1.2-1.8, P<0.0001), but VEA during exer- 
cise was not predictive (adjusted HR 1.1, 95% CI 0.9-1.4, P--0.18).Concluelon: As we 
hypothesized, VEA during recovery after exercise predicts mortality, but VEA only during 
exercise does not. 
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830FO-5 Exercise-Induced Ventricular Premature Beats Are 
Associated With Increased Cardiovascular Mortality: 
The Framingham Heart Study 
All Morshedi-Meibodi. Jane Evans, Daniel Levy, Martin G. Larson, Ramachandran 
Vasan, NHLBrs Framingham Heart Study, Framingham, Massachusetts, Boston 
University School of Medicine, Boston, Massachusetts. 
Background: There is controversy regarding the prognostic impact of exercise-induced 
ventricular premature beats (VPB). While eadier studies reported no adverse relation, the 
Paris Prospective Study recently reported an increase risk of death in men with exercise- 
induced VPBs. 
Methods: We evaluated 2,840 Framingham Offspring Study subjects (1,388 men, mean 
age 43 years) who were free of cardiovascular disease and underwent a heart rata-lim- 
fled exercise test according to the Bruce protocol during a routine examination. 780 sub- 
jects (27%) had VPBs during the exercise (median of 0.22 VPBs/minute of exercise). 
Subjects were divided into three groups based on the numbers of VPBs/minute of exer- 
cise: those without any VPBs, those below (low frequency VPBs) and those above the 
median (high frequency VPBs). Cox proportional hazard regression models incorporating 
established risk factors (age, sex, diabetes, hypertension, smoking, total and HDL cho- 
lesterol) and adjusting for interim cardiovascular disease (CVD) events were used to 
examine the association of exemise-induced VPBs at the baseline examination with risk 
of death due to coronary heart disease (CHD), CVD (including CHD and other vascular 
events), and all-cause mortality on follow up, 
Results: On follow up (mean 15 years), 159 subjects died (38 CVD deaths [31 men), 29 
CHD deaths [24 men]). Exercise-induced VPBs were associated with increased risk of 
all-cause mortality [multivarieble HR for trend across 3 groups of 1.38, 95% CI, 1.14- 
1.65], CHD-death (HR 1.82, 95% CI, 1.20-2.74] and CVD-death [HR 1.91, 95% CI, 1.33- 
2.73]. The high VPB frequency group was associated with the greatest risk of all three 
outcomes. 
Conclusions: In our large community-based sample of men and women, exercise- 
induced VPBs identified a group at increased sk of death secondary to CHD, CVD, and 
all-cause mortality. Additional studies are needed to examine the utility of the exercise- 
induced VPBs for risk stratification. 
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830FO-6 Heart Rate Recovery Improved in a Cohort of Adults 
After Cardiac Rehabilitation 
Ema Obenza Nishime. Christopher R, Cole, Gregory S, Wallace, Robert J. Rosnick, 
Claire E. Pothier Snader, Eugene H. Blackstone, Gordon Blackburn, Michael S, Lauer, 
Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: An abnormal heart rate recovery after exercise predicts mortality, As exer- 
cise modulates autonomic function and heart rate recovery reflects vagal tone, we 
hypothesized that cardiac rehabilitation would favorably impact heart rate recovery. 
Methods: Consecutive adults (n=595, 61_+11 years, 78% male) who underwent symp- 
tom-limited exercise tests before and after Phase II cardiac rehabilitation were studied. 
Heart rate recovery (HRR) was the difference of heart rate at peak exercise and one- 
minute later with _< 12 bpm abnormal. 
Results: HRR improved from a median of 13 bpm before rehabilitation to 17 bpm affer- 
wards (P<0.0001). There were 287 adults (48%) with abnormal baseline HRR; 161 
(56%) were still abnormal afterwards. Predictors of failure to improve HRR included older 
age (for 10 years, adjusted Odd Ratio [OR] 1.3, 95% CI 1.0-1.7, p=0.03), lesser change 
in exercise capacity (for 1.5 METs, adjusted OR 1.3, 95% CI 1,1-1.6, p=0.002). During 4 
years, there were 42 deaths. After adjusting for age, gender, and change in exercise 
capacity, abnormal baseline HRR predicted eath (12% vs. 3%, adjusted HR 4.0, 95% CI 
1.8-8.8, p=0.0006). Failure to improve an abnormal HRR tended to predict higher mortal- 
ity (adjusted HR 2.0, 95% CI 0.9-4.3, P=0,08) (Figure). 
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Conclusion: Heart rate recovery improved in patients affer cardiac rehabilitation. 
Although we cannot exclude regression to the mean, the tendency of an improved HRR 
to predict lower mortality suggests that this was prognostically meaningful. 
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1133-137 Myocardial Overexpresaion of the Cardiac b-Adrenergic 
Receptor Kinaee-1 Inhibitor (BARKI) Delay the 
Development of Cardiomyopsthy Induced by 
Myocardial Expression of Monocyte Chemo-Tactic 
Protein-1 (MCP-1) 
Samer J. Khouri, Philip Binkley, Walter Koch, Pappechan Kolattukudy, Ohio State 
Universi~ Columbus, Ohio, Duke University, Durham, North Carolina. 
Background: Targeted expression of MCP-1 in the cardiomyocytes induces cardiomy- 
opathy in a murine model. We hypothesized that overexpression ofBARKI in these MCP- 
1 mice may delay the progression of ventricular remodeling. Methods: Studies were per- 
formed on mice with targeted myocardial expression of BARKI, MCP-1, BARKI and 
MCP-1 (MCP-BARKI) and wild-type mice as controls. 2D and M-mode echo were per- 
formed at baseline, 1 and 2 month. Results: At baseline MCP-1 and MCP-BARKI mice 
did not have a significant difference in mass 68.4 ± 0.6 & 68.6 ± 0.7 mg nor in EF 42 ± 5 
& 44 -+ 3 % and they were significantly different from BARKI mice and controls (Figures). 
The MCP-BARKI and MCP-1 mice increased LV mass to the same extent at one month. 
However, at two months, the LV mass was significantly greater in the MCP-1 mice as 
compared to MCP-BARKI mice 92.9 ± 83 and 80.0 ± 1.3 mg, respectively. BARKI and 
control mice had mild increase in cardiac mass, but significantly different from MCP-1 
and MCP-BARKI mice 69.9 + 0.4 and 70.9 + 1.7, respectively. The EF did not show sig- 
nificant change over time (figure 2). Conclusion: 13ARKI overexpression does not pre- 
serve myocardial contractility in mice with cardiomyopathy that express MCP-1, but has 
a significance ffect on the cardiac mass. This suggests a significant influence of BARKI 
overexpression i  preventing cardiac remodeling. This may suggest a novel molecular 
target for future therapies targeted at the prevention of progressive ventricular remodel- 
ing in patients with heart failure. 
1133-138 Down-Regulation of Sodium Current in Heart Failure: 
Rescue by Beta-Blockers 
AIbertas I. Undrovina~, Victor A. Maltsev, Hani N. Sabbah, Henry Ford Heart and 
Vascular institute, Detroit, Michigan. 
Background: Ion channel remodeling is believed to provide a substrate for ventdcular 
arrhythmias in heart failure (HF). We recently showed that Na + channels (NaCh) respon- 
sible for excitation generation and propagation i  the heart are down-regulated inchronic 
infarction-induced dog HF model, a feature that suggests possible involvement of these 
channels in ventdcular arrhythmias. While ~-blockers (BB) are known to significantly 
reduce the risk of the ventdcular arrhythmias and sudden cardiac death in patients with 
HF, the cellular and ionic mechanisms of this beneficial effect remain unknown. In this 
study, we tested the hypothesis that BB prevent NaCh downregulation i chronic HF. 
Methods: Studies were performed in cardiomyocytes isolated from dogs with chronic HF 
produced by multiple sequential intracoronary microembolizations. In addition to marked 
LV systolic and diastolic dysfunction, dogs with chronic HF also manifests pontaneous 
ventricular arrhythmias and sudden cardiac death occurs in -13% of HF animals. To 
study the effects of BB on the regulation NaCh, HF (LV ejection fraction 28±1%) was pro- 
duced in 12 dogs. Six HF dogs were treated for 3 months with carvedilol (1 mg/kg, twice 
daily) and 6 were untreated and sewed as controls. In addition, cardiomyocytes from 9 
normal dogs were used for comparison. At the end of 3 months of therapy, mid-myocar- 
dial cardiomyocytes were isolated from the LV free wall. The whole-cell maximum Na + 
current (INa) was measured using patch-clamp technique in symmetrical Na + solutions 
([Na]i=[Na]o=Smmol/L) at room temperature. Chronic treatment with carvedilol restored 
INa density in dogs with HF INa density in carvedilol dogs was significantly higher com- 
pared to that of untreated HF dogs (46.4:L-0.9 pNpF vs. 33±3.3 pNpF, P=0.008) and was 
similar to that of normal dogs (48.5±5.1 pNpF). The voltage dependence of steady-stats 
inactivation and activation of INa remained unchanged in both carvedilol-treated and 
untreated HF dogs. 
Conclusion: Down-regulation of NaCh in ventdcular cardiomyocytes caused by chronic 
HF in dog can be prevented by a chronic therapy with 13-blockers. 
